MCAS 2024 Provider Resource Guide





Table of Contents

General MCAS Information	4
What Is MCAS?	4
What is ECDS?	5
Contact Information	5
2024 MCAS Measures	6
Measures Held to Minimum Performance Level.	6
Age Ranges of Measures	8
Common Codes Reference	9
Behavioral Health Domain Measures	11
Follow-Up After Emergency Department Visit for Mental Illness (FUM)	12
Follow-Up After Emergency Department Visit for Substance Use (FUA)	13
Children's Health Domain Measures	15
Child and Adolescent Well-Care Visits (WCV)	16
Childhood Immunization Status (CIS)	17
Developmental Screening in the First Three Years of Life (DEV)	19
Immunizations for Adolescents (IMA)	20
Lead Screening in Children (LSC)	23
Topical Fluoride for Children (TFL-CH)	24
Well-Child Visits in the First 30 Months of Life (W30)	25
Chronic Disease Management Domain Measures	26
Asthma Medication Ratio (AMR)	27
Controlling High Blood Pressure (CBP)	29
Glycemic Status Assessment for Patients with Diabetes (GSD) *Formerly known as He Control for Patients with Diabetes (HBD): HbAlc Poor Control (>9%)	
Reproductive Health Domain Measures	32
Chlamydia Screening in Women (CHL)	33
Timeliness of Prenatal Care (PPC-Prenatal)	34
Postpartum Care (PPC-Post)	36
Cancer Prevention Domain Measures	38
Breast Cancer Screening (BCS-E)	39

Cervical Cancer Scree	ening (CCS)	 •••••	 4

General MCAS Information

What Is MCAS?

Annually California's Department of Health Care Services (DHCS) selects a set of performance measures for reporting by Medi-Cal managed care health plans (MCPs) which becomes the Managed Care Accountablity Set or MCAS. MCAS MY 2024 has 18 measures that will be held to the minimum performance level (MPL) or 50th percentile in 2024.

MCAS Performance Measures can be selected from a variety of stewards including:

- National Committee for Quality Assurance's (NCQA) <u>Healthcare Effectiveness Data and</u> Information Set (HEDIS®)
- Centers for Medicare & Medicaid Services' (CMS) Child & Adult Core Sets
- The Joint Commission (TJC)
- Dental Quality Alliance (DQA)

Measures have several different data reporting metholologies including:

- Administrative data:
 - Obtained from claims (outpatient office visits, pharmacy data, lab/radiology services) via billing/diagnosis codes
 - Obtained from encounter data via electronic health record exchange and immunization registries
- Hybrid data is obtained from a combination of administrative data and data obtained through medical record review.
- Electronic Clinical Data Systems (ECDS) which is a network of data containing member PHI and records

MCAS MY 2024 has a total of 27 Administrative, 8 Hybrid/Administrative, 1 ECDS/Admin, and 6 ECDS only measures. Held to the minimum performance levels alone, are 9 Administrative, 8 Hybrid/Administrative, 1 ECDS/Admin.

What is ECDS?

The National Committee for Quality Assurance (NCQA) defines <u>E</u>lectronic <u>C</u>linical <u>D</u>ata <u>S</u>ystems (ECDS) in this way:

HEDIS quality measures reported using ECDS inspire innovative use of electronic clinical data to document high-quality patient care that demonstrates commitment to evidence-based practices. Organizations that report HEDIS using ECDS encourage exchange of the information needed to provide high-quality services, ensuring that the information reaches the right people at the right time.

The ECDS reporting standard represents a step forward in adapting HEDIS to accommodate the expansive information available in electronic clinical datasets used for patient care and quality improvement.

ECDS are the network of data containing a plan member's personal health information and records of their experiences within the health care system. They may also support other care-related activities directly or indirectly, including evidence-based decision support, quality management and outcome reporting. Data in these systems are structured such that automated quality measurement queries can be consistently and reliably executed, providing results quickly and efficiently to the team responsible for the care of health plan members.

Health plans that establish an enterprise network of interoperable electronic data systems will foster a member-centered, team-based approach to improving health care quality and better communication across health care service providers. Visit http://www.ncqa.org/ecds for more information and FAQs about ECDS reporting.

In measurement year (MY) 2024 DHCS requires health plans to submit 6 MCAS measures using ECDS methodology from both MPL and Report Only lists.

It is anticipated that as NCQA transitions more HEDIS® measures into ECDS-only reporting, DHCS will likely require plans to submit more and more MCAS measures digitally as well. To aid this gradual transition, providers/practices can allow KHS a data feed to support ECDS. Connect with your Provider Relations Representative to set up a meeting with our Business Intelligence Department.

Contact Information

QUALITY PERFORMANCE MCAS TEAM
Aurora De La Torre, MCAS/HEDIS Program
Manager
Andrea Longoria, QP RN I
Laura Mudge, QP RN, I
Monica Bandaru, QP Senior Operational Analyst
Evangelina Ramirez, Senior QP Coordinator
Isenia Calderon, MCAS Coordinator

2900 Buck Owens Blvd. Bakersfield, Ca 93308

661.664.500 (in Bakersfield) 800.391.2000 (outside of Bakersfield)


KHSMCASTeam@khs-net.com

2024 MCAS Measures

Measures Held to Minimum Performance Level

Name	ACRONYM	Steward	Түре
Follow-Up After ED Visit for Mental Illness- 30 days	FUM	NCQA	Administrative
Follow-Up After ED Visit for Substance Abuse- 30 days	FUA	NCQA	Administrative
Child and Adolescents Well-Care Visits	WCV	NCQA	Administrative
Childhood Immunizations Status- Combination 10	CIS-10	NCQA	Hybrid/Admin
Developmental Screening in the First Three Years of Life	DEV	CMS	Administrative
Immunizations for Adolescents- Combination 2	IMA-2	NCQA	Hybrid/Admin
Lead Screening in Children	LSC	NCQA	Hybrid/Admin
Topical Fluoride for Children	TFL-CH	DQA	Administrative
Well-Child Visits in the First 30 Months of Life - 0 to 15 Months- Six or More Well-Child Visits	W30-6+	NCQA	Administrative
Well-Child Visits in the First 30 Months of Life- 15 to 30 Months- Two or More Well-Child Visits	W30-2+	NCQA	Administrative
Asthma Medication Ratio	AMR	NCQA	Administrative
Controlling High Blood Pressure	CBP	NCQA	Hybrid/Admin
Glycemic Status Assessment for Patients with Diabetes	GSD	NCQA	Hybrid/Admin
Chlamydia Screening in Women	CHL	NCQA	Administrative
Prenatal and Postpartum Care: Timeliness of Prenatal Care	PPC- Pre	NCQA	Hybrid/Admin
Prenatal and Postpartum Care: Postpartum Care	PPC- Post	NCQA	Hybrid/Admin
Breast Cancer Screening	BCS-E	NCQA	ECDS
Cervical Cancer Screening	CCS	NCQA	Hybrid/Admin


Age Ranges- All Measures



^{*}PPC measure does not have specified age range, it is estimated based on childbearing age.

[^]For FUA and FUM measures there is no age limit, 100 is a max estimate.

Age Ranges- Pediatric




Common Codes Reference

Common Medi-Cal Managed Care Accountability Set (MCAS) Codes MY2024

*This list is not all-inclusive. Highlights are Pay-for-Performance Measures. Italics are Hybrid Measures requiring medical record review. Bolded are linked to Member Rewards.

Measure	Codes			
AMR: Asthma Medication Ratio	ICD-10: J45.21. J45.22, J45.30-J45.32, J45.40-J45.42, J45.50-J45.52, J45.901, J45.902, J45.909, J45.991, J45.998			
BCS: Breast Cancer Screening	CPT: 77061 to 77067			
CCS: Cervical Cancer Screening	CPT: 88141-88143, 88147, 88148, 88150, 88152, 88153, 88164-88167, 88174, 88175, 87624, 87625 HCPCS: G0123, G0124, G0141, G0143-G0145, G0147, G0148, G0476, P3000, P3001, Q0091			
CIS Combo 10: Childhood Immunization Status	*Indicates combination vaccines CPT: DTaP: 90697, 90698*, 90700, 90723* IPV: 90697, 90698*, 90713, 90723* MMR: 90707, 90710* Hib: 90644, 90647, 90648, 90697, 90698*, 90748* Hep B: 90697, 90723*, 90740, 90744, 90747, 90748* HCPCS: G0010 VZV: 90710*, 90716 PCV: 90670, 90671 Hep A: 90633 RV: 90681 (2-dose), 90680 (3-dose) Flu: 90655, 90657, 90660, 90661, 90672, 90673, 90674, 90685-90689, 90756 HCPCS: G0008			
CHL: Chlamydia Screening in Women	CPT: 87110, 87270, 87320, 87490-87492, 87810, 0353U			
CBP: Controlling High Blood Pressure, Ages 18-85	ICD-10: I10 CPT II Codes: Systolic: Diastolic: <130 mm Hg: 3074F <80 mm Hg: 3078F 130-139 mm Hg: 3075F ≥140 mm Hg: 3077F ≥90 mm Hg: 3080F			
DEV: Developmental Screening in the First Three Years of Life	ICD-10: Z13.42, Z00.129, F82 CPT: 96110, 96112, 96113			
FUM: Follow-Up After Emergency Department Visit for Mental Illness	*This measure contains extensive code sets for Diagnoses and Eligible Follow-Up Codes. Please contact Kern Family MCAS Team for more information. ICD-10: F20 intermittently through F94, T14, T36-T65, T71. CPT: 98960-98962, 98966-98968, 98970-98972, 99202-99205,			

Measure	Codes
	99391-99397. HCPCS: G0409, H0004, G0176, T1015, G0071, G2012
FUA: Follow-Up After Emergency Department Visit for Substance Use	*This measure contains extensive code sets for Diagnoses and Eligible Follow-Up Codes. Please contact Kern Family MCAS Team for information. ICD-10: F10-F19, Z71.41, Z71.51 CPT: 98960-98962, 99211-99215, 99391-99397, 99421-99423, 99441-99443. HCPCS: G0463, H0004, H0037, H2020, G2012, G2086
GSD: Glycemic Status Assessment for Patients with Diabetes. Formerly known as Hemoglobin A1C Control for Patients with Diabetes (HBD)	ICD-10: E10, E11, E13, O24 CPT: 83036, 83037 CPT II: Most recent A1C <7.0 = 3044F Most recent A1C ≥7.0 to <8.0 = 3051F Most recent A1C ≥8.0 to ≤9.0 = 3052F Most recent A1C >9.0 = 3046F LOINC: 97506-0 (ID's glucose management indicator values)
IMA Combo 2: Immunizations for Adolescents	CPT: Meningococcal: 90619, 90733, 90734 Tdap: 90715 HPV: 90649, 90650, 90651
LSC: Lead Screening in Children	CPT: 83655
PPC: Prenatal Care	*This measure contains extensive code sets for Diagnoses and Eligible Visit Codes. Please contact Kern Family MCAS Team for information. ICD-10: 009, Z34 CPT: 98966-98968, 98970-98972, 99202-99205, 99211-99215, 99241-99245, 99441-99443, 99500 CPT II: 0500F-0502F HCPCS: G0463, G2012, G2252, T1015
PPC: Postpartum Care	ICD-10: Z01.411, Z01.419, Z01.42, Z30.430, Z39.1, Z39.2 CPT: 57170, 58300, 59400, 59410, 59430, 59510, 59515, 59610, 59614, 59618, 59622, 99501 CPT II: 0503F
TFL-CH: Topical Fluoride for Children	CPT: 99188 (covered up to age 5)
W30: Well-Child Visits in the First 30 Months of Life	ICD-10: Z00.110, Z00.111, Z00.121, Z00.129, Z00.2, Z76.1, Z76.2 CPT: 99381-99385, 99391-99395, 99461 HCPCS: G0438, G0439 *Add Modifier 25 on a sick visit to capture the Well Child Visit
WCV: Child & Adolescent Well- Care Visits, Ages 3-21	ICD-10: Z00.00, Z00.01, Z00.121, Z00.129, Z00.2, Z00.3, Z01.411, Z01.419, Z02.5, Z76.1, Z76.2 CPT: 99381-99385, 99391-99395, 99461 HCPCS: G0438, G0439 *Add Modifier 25 on a sick visit to capture the Well Child Visit



Follow-Up After Emergency Department Visit for Mental Illness (FUM)

Measure Description:

The percentage of emergency department (ED) visits for members 6 years of age and older with a principal diagnosis of mental illness or intentional self-harm, who had a follow-up visit for mental illness. Two rates are reported:

- The percentage of ED visits for which the member received follow-up within 30 days of the ED visit (31 total days).
- The percentage of ED visits for which the member received follow-up within 7 days of the ED visit (8 total days).

Required Exclusions:

Exclude members who meet *any* of the following criteria:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.

- Follow-up can be with *any* practitioner, with a principal diagnosis of a mental health disorder *OR* with a principal diagnosis of intentional self-harm *and any* diagnosis of a mental health disorder.
- Any of the following meet criteria for a follow-up visit:
 - o An outpatient visit with a principal diagnosis of a mental health disorder
 - An intensive outpatient encounter or partial hospitalization with a principal diagnosis of a mental health disorder.
 - A community mental health center visit with POS code 53 with a principal diagnosis of a mental health disorder.
 - o Electroconvulsive therapy with a principal diagnosis of a mental health disorder.
 - o A telehealth visit with a principal diagnosis of a mental health disorder.
 - o A telephone visit with a principal diagnosis of a mental health disorder.
 - o An e-visit or virtual check-in with a principal diagnosis of a mental health disorder.
- Visits on the same day of the ED visit are considered compliant.
- Allow KHS a data feed to support ECDS. Contact your Provider Network representative to get connected with our Business Intelligence team.

Follow-Up After Emergency Department Visit for Substance Use (FUA)

Measure Description:

The percentage of emergency department (ED) visits among members age 13 years and older with a principal diagnosis of substance use disorder (SUD), or any diagnosis of drug overdose, for which there was follow-up. Two rates are reported:

- The percentage of ED visits for which the member received follow-up within 30 days of the ED visit (31 total days).
- The percentage of ED visits for which the member received follow-up within 7 days of the ED visit (8 total days).

Required Exclusions:

Exclude members who meet *any* of the following criteria:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.


Ways To Improve MCAS Rates:

- Allow KHS a data feed to support ECDS. Contact your Provider Network representative to get connected with our Business Intelligence team.
- A follow-up visit or a pharmacotherapy dispensing event within 7 days after the ED visit (8 total days), OR within 30 days after the ED visit (31 total days), respectively. Include visits and pharmacotherapy events that occur on the date of the ED visit.

For both 7 and 30 day indicators, *any* of the following meet criteria for a follow-up visit:

- An outpatient visit with any diagnosis of SUD, substance use, or drug overdose.
- An outpatient visit with a mental health provider.
- An intensive outpatient encounter or partial hospitalization with any diagnosis of SUD, substance use, or drug overdose.
- An intensive outpatient encounter or partial hospitalization with a mental health provider.
- A non-residential substance abuse treatment facility visit with any diagnosis of SUD, substance use, or drug overdose.
- A non-residential substance abuse treatment facility visit with a mental health provider.
- A community mental health center visit with any diagnosis of SUD, substance use, or drug overdose.
- A community mental health center visit with a mental health provider.
- A peer support service with any diagnosis of SUD, substance use, or drug overdose.

- An opioid treatment service that bills monthly or weekly with any diagnosis of SUD, substance use, or drug overdose.
- A telehealth visit with any diagnosis of SUD, substance use, or drug overdose.
- A telehealth visit with a mental health provider.
- An e-visit or virtual check-in with any diagnosis of SUD, substance use, or drug overdose.
- An e-visit or virtual check-in with a mental health provider.
- A substance use disorder service.
- A behavioral health screening or assessment for SUD or mental health disorders.
- A substance use service (Substance Use Services Value Set).
- A pharmacotherapy dispensing event or medication treatment event.



Child and Adolescent Well-Care Visits (WCV)

Measure Description:

The percentage of members 3–21 years of age who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during the measurement year.

Required Exclusions:

Exclude members who meet either of the following criteria:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.

- Use appropriate billing codes.
- Check for gaps in care at every office visit.
- Sports/day care physicals can be used as an annual well-care visit by performing the required services and submitting appropriate codes.
- Use standardized templates in EMRs and charts that allow for checkmarks to document health education, counseling, and/or anticipatory guidance.
- Outreach to members with gaps in care or who miss appointments with letters, emails, reminder calls, and/or text messages.
- Schedule appointments during school holidays/breaks and offer extended/weekend hours for annual well-care visits.

Childhood Immunization Status (CIS)

Measure Description:

The percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV); one measles, mumps and rubella (MMR); three haemophilus influenza type B (HiB); three hepatitis B (HepB), one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (HepA); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday.

Required Exclusions:

Exclude children who meet *any* of the following criteria:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.
- Members who had a contraindication to a childhood vaccine (Contraindications to Childhood Vaccines Value Set) on or before their second birthday.

Medical Record Documentation:

- Evidence that the antigen was rendered from one of the following:
 - o A note indicating the name of the specific antigen and the date of the immunization.
 - A certificate of immunization prepared by an authorized health care provider or agency including the specific dates and types of immunizations administered.
- For documented history of illness or anaphylaxis, there must be a note indicating the date of the event, which must have occurred by the member's second birthday.
- Notes in the medical record indicating that the member received the immunization "at delivery" or "in the hospital" may be counted toward the numerator only for immunizations that do not have minimum age restrictions (e.g., before 42 days after birth). A note that the "member is up to date" with all immunizations but which does not list the dates of all immunizations and the names of the immunization agents does not constitute sufficient evidence of immunization for HEDIS reporting.
- Immunizations documented using a generic header or "DTaP/DTP" can be counted as evidence of DTaP.
- Immunizations documented using a generic header (e.g., polio vaccine) or "IPV/OPV" can be counted as evidence of IPV.
- For rotavirus, if documentation does not indicate whether the two-dose schedule or three-dose schedule was used, health plans must assume a three-dose schedule and the provider is responsible for providing evidence that three doses were administered.

- Update the member's chart/EMR with any vaccines given at birth or by other providers.
- Utilize California's Immunization Registry (CAIR) to check for needed vaccinations and submit vaccines given to the registry to ensure continuity of care.
- Check for needed vaccinations at every visit.
- Outreach to members with gaps in care or who miss vaccination appointments with letters, emails, reminder calls, and/or text messages.
- Schedule the 2-year well-child visit on or before the 2nd birthday vaccines given after the 2nd birthday will not be compliant.

Developmental Screening in the First Three Years of Life (DEV)

Measure Description

Children 1 to 3 years of age who were screened for risk of developmental, behavioral, and social delays using a standardized screening tool on or **before** their 1st, 2nd, and 3rd birthdays.

Document Requirements

- A note indicating the date the screening was performed.
- The standardized tool used
- Screening result or screening score
 - o The following domains must be included: motor (fine and gross), language, cognitive, and social-emotional.

Tools must meet the following criteria:

- Developmental domains: The following domains must be included in the standardized developmental screening tool: motor (fine and gross), language, cognitive, and social-emotional.
- Established Reliability: Reliability scores of approximately 0.70 or above.
- Established Findings Regarding the Validity: Validity scores for the tool must be approximately 0.70 or above. Measures of validity must be conducted on a significant number of children and using an appropriate standardized developmental or social-emotional assessment instrument(s).
- Established Sensitivity/Specificity: Sensitivity and specificity scores of approximately 0.70 or above.

Example developmental screening tools that meet criteria for the measure:

The following tools meet the above criteria and are included in the Bright Futures Recommendations for Preventive Care (see here: https://downloads.aap.org/AAP/PDF/periodicity_schedule.pdf), which reference the updated January 2020 American Academy of Pediatrics (AAP) Statement:

- Ages and Stages Questionnaire 3rd Edition (ASQ-3)
- Parents' Evaluation of Developmental Status (PEDS) Birth to age 8
- Parent's Evaluation of Developmental Status Developmental Milestones (PEDS-DM)
- Survey of Well-Being in Young Children (SWYC)

Tools included in the 2006 Statement that meet the above criteria but were not listed in the 2020 Statement (as they often are not used by primary care providers in the context of routine well-child care) include the following:

- Battelle Developmental Inventory Screening Tool (BDI-ST) Birth to 95 months
- Bayley Infant Neuro-developmental Screen (BINS) 3 months to age 2
- Brigance Screens-II Birth to 90 months
- Child Development Inventory (CDI) 18 months to age 6
- Infant Development Inventory Birth to 18 months

The tools listed above are not specific recommendations but are examples of tools cited in Bright Futures that meet the above criteria.

Tools must include screening for 4 domains: motor, language, cognitive and social-emotional.

Developmental Tools that do NOT meet criteria for the measure:

- M-Chat: Social Emotional Development or Autism
- ASQ:SE Social Emotional Development or Autism

It is important to note that this measure is anchored to recommendations related to global developmental screening using tools that identify risk for developmental, behavioral, and social delays.

Ways To Improve MCAS Rates:

- Use appropriate billing codes.
- Assess developmental milestones at every office visit and conduct developmental screening at 9, 18, and 24-30 months.
- Screen more frequently for children with increased risk factors such as:
 - o Preterm birth.
 - o Low birth weight,
 - o Lead exposure,
 - o Long lasting health problems or conditions.
- Educate parents/guardians to monitor for developmental milestones such as:
 - o taking a first step,
 - o smiling for the first time,
 - o waving "bye",
 - o crawling,
 - o walking, etc.
- Mail the questionnaire to parents/guardians prior to the visit or make it available online so it can be completed prior to the visit.

FYI:

- As noted in the Bright Futures periodicity schedule, screening should occur per "Promoting Optimal Development: Identifying Infants and Young Children with Developmental Disorders Through Developmental Surveillance and Screening" and is accessible at: https://pediatrics.aappublications.org/content/145/1/e20193449.
- The article also includes more information about the developmental screening tools that meet the measure criteria and is available at https://aap2.silverchair-

<u>cdn.com/aap2/content_public/journal/pediatrics/145/1/10.1542_peds.2019-3449/7/peds_20193449supplementarydata.pdf.</u>

- During the development of this measure, it was determined that the ASQ:SE and M-CHAT screening tools were too specific because they screen for a domain-specific condition (social emotional development or autism, respectively), rather than a full, general assessment of developmental delays.
- States should use the "Deviations from Measure Specifications" field to document any deviations from the specifications for this measure.

Immunizations for Adolescents (IMA)

Measure Description:

The percentage of adolescents 13 years of age who had one dose of meningococcal vaccine, one tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine, and have completed the human papillomavirus (HPV) vaccine series by their 13th birthday.

Required Exclusions:

Exclude children who meet *any* of the following criteria:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.

Medical Record Documentation:

- A certificate of immunization prepared by an authorized health care provider or agency including the specific dates and types of immunizations administered.
- In the case of illness or anaphylaxis, a note must be present indicating the date of the event (must have occurred by the child's thirteenth birthday).
- For the two-dose HPV vaccination series, there must be at least 146 days between the first and second dose of the HPV vaccine.

- Update the member's chart/EMR with any vaccines given at birth or by other providers.
- Utilize California's Immunization Registry (CAIR) to check for needed vaccinations and submit vaccines given to the registry to ensure continuity of care.
- Check for needed vaccinations at every visit.
- Outreach to members with gaps in care or who miss vaccination appointments with letters, emails, reminder calls, and/or text messages.
- Schedule a series of vaccination appointments.

Lead Screening in Children (LSC)

Measure Description:

The percentage of children 2 years of age who had one or more capillary or venous lead blood test for lead poisoning by their second birthday.

Required Exclusions:

Exclude members who meet either of the following criteria:

- Members who use hospice services elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.

Medical Record Documentation:

Documentation in the medical records must include *both* of the following:

- A note indicating the date the test was performed
- The result or finding.

- Educate parents/guardians about the dangers of lead poisoning and the importance of testing.
- Consider a standing order in-office (capillary) lead screening.
- Perform blood lead screening:
 - o If there is no documented evidence of lead screening for children up to 72 months old,
 - o Beginning at 6 months of age for children identified as high risk for lead exposure,
 - o At 12 to 15 months of age for children identified as low risk for lead exposure,
 - o If requested by a parent or guardian,
 - o Whenever there is a change which increases the child's risk of lead exposure.
- Outreach to members with gaps in care or who miss appointments with letters, emails, reminder calls, and/or text messages.

Topical Fluoride for Children (TFL-CH)

Measure Description:

Children and adolescents up to age 20 should receive at least **two (2)** fluoride varnish applications during the measurement year.

- United States Preventive Services Task Force (USPSTF) recommends that PCPs apply fluoride varnish to the primary teeth of all infants and children starting at the age of primary tooth eruption.
- American Academy of Pediatrics (AAP) recommends application of fluoride varnish at least once every 6 months, and preferably every 3 months, starting at tooth eruption.
- Because of the high efficacy of fluoride varnish, it is now being applied in non-dental settings.
- The application is quick, easy, and painless, and can be delegated to nursing and medical assistant staff.

Required Exclusions:

Exclude children who meet *any* of the following criteria:

- Enrolled in hospice or received hospice services any time during the measurement year.
- Died during the measurement year.

- CPT code 99188 (application of topical fluoride varnish by a physician or other qualified health care professional) is reimbursable for children through five years of age, up to three times per year.
- If you do not have the supplies or training to perform this in-office, or if the child is age six or older, you may refer the child to a dental provider. If interested, contact your MCAS or Provider Relations Teams to learn more about fluoride resources for your medical practice.
- Check for gaps in care at every office visit.
- Outreach to members with gaps in care or who miss appointments with letters, emails, reminder calls, and/or text messages.

Well-Child Visits in the First 30 Months of Life (W30)

Measure Description:

The percentage of members who had the following number of well-child visits with a PCP during the last 15 months. The following rates are reported:


- Well-Child Visits in the First 15 Months. Children who turned 15 months old during the measurement year: Six or more well-child visits.
- Well-Child Visits for Age 15 Months—30 Months. Children who turned 30 months old during the measurement year: Two or more well-child visits.

Required Exclusions:

Exclude members who meet either of the following criteria:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.

- Use appropriate billing codes.
- Check for gaps in care at every office visit.
- Day care physicals can be used as an annual well-care visit by performing the required services and submitting appropriate codes.
- Use standardized templates in EMRs and charts that allow for checkmarks to document health education, counseling, and/or anticipatory guidance.
- Outreach to members with gaps in care or who miss appointments with letters, emails, reminder calls, and/or text messages.
- Offer extended/weekend hours for annual well-care visits.



Asthma Medication Ratio (AMR)

Measure Description:

The percentage of members 5–64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year.

Required Exclusions:

Exclude members who met any of the following criteria:

- Members who had a diagnosis that requires a different treatment approach than members with asthma, any time during the member's history through December 31 of the measurement year.
- Members who had no asthma controller or reliever medications dispensed during the measurement year.
- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.

Good to Know:

Please note, the AMR measure is based on clinical recommendations that for patients with an official diagnosis of asthma, at least 50 percent of their medications should be **controller** medications. Measuring the ratio looks at whether the member is receiving appropriate medication treatment to "control" the asthma.

Day's supply is used to count units of medication for oral medications, but not used to count inhalers or injections. Each inhaler or injectable medication dispensing event is seen as 1 unit of medication, regardless of day's supply.

NCQA derived at the 0.50 ratio in the measure based on feedback from experts on the Respiratory Measurement Advisory Panel and also from clinical evidence. Several studies have found that patients who have an asthma medication ratio of 0.50 or higher are less likely to be hospitalized or have an ED visit for asthma exacerbations and have fewer oral corticosteroid dispensing events, which is another indicator of poor asthma control.

- Avoid using asthma diagnosis codes for asthma-like symptoms if not formally diagnosing.
- Educate patients on use of asthma medications and importance of using their prescribed asthma controller as prescribed.
- Provide reminders to your patients to fill controller medications.
- Refer patients for health management interventions and coaching by contacting disease management and/or health education at Kern Health Systems.
- Through Community Support Services (CSS), KHS has an Asthma Remediation Program. The program helps members make necessary modifications to their home or living environment, to

include the pur submitted thou www.kernfami	n maintain a healthy a chasing of air purifie gh the KHS Provider lyhealthcare.com, un	rs and other med Portal or on our a der the Providers	ical supplies. An main website, tab, Community	authorization can b
Submit a Refer	ral: <u>css-referral-form</u>	n.pdf (cloudinary	<u>.com)</u> .	

Controlling High Blood Pressure (CBP)

Measure Description:

The percentage of members 18–85 years of age who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately controlled (<140/90 mm Hg) during the measurement year.

Required Exclusions:

Exclude members who meet *any* of the following criteria:

- Members who use hospice or palliative care services any time during the measurement year.
- Members who die any time during the measurement year.
- Members with a diagnosis that indicates end-stage renal disease (ESRD) any time during the member's history on or prior to December 31 of the measurement year.
- Members with a procedure that indicates ESRD: dialysis, nephrectomy, or kidney transplant any time during the member's history on or prior to December 31 of the measurement year.
- Members with a diagnosis of pregnancy any time during the measurement year.
- Members 66–80 years of age with at least two instances of frailty *and* advanced illness or disease within the measurement year.
 - Examples of Frailty include dependence on Durable Medical Equipment (DME), oxygen or respiratory devices. Diagnoses of pressure ulcers, falls, paralysis, need for skilled nursing visits or aide, failure to thrive, or any other abnormalities of gait and mobility.
- Members 81 years of age and older as of December 31 of the measurement year with at least two indications of frailty.

Medical Record Documentation:

For purposes of MCAS reporting, the last blood pressure of the measurement year is identified, excluding readings occurring during acute inpatient stays, ED visits, or on the same day as diagnostic testing or therapeutic procedures.

- Use appropriate billing codes, including use of CPT II quality tracking codes to reduce the number of medical records your practice will need to provide KHS during MCAS audit season.
- Electronic BP readings reported by the member can be used for reporting.
- BPs must be documented as a distinct numeric value and not a range/threshold.

Glycemic Status Assessment for Patients with Diabetes (GSD)

*Formerly known as Hemoglobin A1c Control for Patients with Diabetes (HBD): HbA1c Poor Control (>9%)

Measure Description:

The percentage of members 18–75 years of age with diabetes (types 1 and 2) whose most recent glycemic status (hemoglobin A1c [HbA1c] or glucose management indicator [GMI]- specifically a continuous glucose monitor (CGM)) was at the following levels during the measurement year:

- Glycemic Status <8.0%.
- Glycemic Status >9.0%.

FYI: For purposes of auditing glycemic status, there are two ways KHS will identify members with diabetes: by claim/encounter data, and by pharmacy data, per NCQA HEDIS technical specifications. Members will be brought into the eligible population for this measure using the following:

- Members with at least two diagnoses of diabetes on different dates during the measurement year or the year prior.
- Members who were dispensed insulin or hypoglycemics/ antihyperglycemics during the measurement year or the year prior to the measurement year *and* have at least *one* diagnosis of diabetes during the measurement year or the year prior to the measurement year.

Required Exclusion:

Exclude members who meet *any* of the following criteria:

- Members who use hospice services or receive palliative care any time during the measurement year.
- Members who die any time during the measurement year.
- Members 66 years of age and older as of December 31 of the measurement year with at least two instances of frailty *and* advanced illness or disease within the measurement year.
 - Examples of Frailty include dependence on Durable Medical Equipment (DME), oxygen or respiratory devices. Diagnoses of pressure ulcers, falls, paralysis, need for skilled nursing visits or aide, failure to thrive, or any other abnormalities of gait and mobility.
- Dispensed dementia medication.

Medical Record Documentation:


• At a minimum, documentation in the medical record must include a note indicating the date when the glycemic status assessment was performed and the result.

- When identifying the most recent glycemic status assessment (HbA1c or GMI), GMI values
 must include documentation of the continuous glucose monitoring data date range used to derive
 the value. Per NCQA, clinical practice guidelines from the American Diabetes Association
 (ADA) recommend at least 14 days of continuous glucose monitor wear for calculation of
 standardized CGM metrics, including GMI. The terminal date in the range will be used to assign
 assessment date.
- If multiple glycemic status assessments were recorded for a single date, the lowest result will be used.
- GMI results collected by the member and documented in the member's medical record are eligible for use in reporting (provided the GMI does not meet any exclusion criteria). There is no requirement that there be evidence the GMI was collected by a PCP or specialist.
- Ranges and thresholds do not meet criteria for this indicator. A distinct numeric result is required for numerator compliance. "Unknown" is not considered a result/finding.
- How providers document CGM data in a patient chart is outside the scope of HEDIS. NCQA does not have criteria related to how GMI is calculated, as it may depend on how data from CGM devices are shared with providers and included in the chart. For example, GMI may be an automated calculation of the EMR, calculated by the provider, or calculated by the CGM device manufacture and included in a standard report. The expectation is that the GMI value is included in the chart for medical record review.
- For administrative reporting, LOINC code 97506-0 (glucose management indicator) is used to identify GMI values.

FYI: The intent of KHS' focus as directed by DHCS, is to capture whether the result of the *most recent* glycemic status assessment (HbA1c or GMI performed during the measurement year) is >9.0% (uncontrolled), missing, or was not done during the measurement year, as documented through laboratory data or medical record review.

*Please note, in this *inverted* measure, a lower rate indicates better performance for this indicator (i.e., low rates of Glycemic Status >9.0% indicate better care).

- Check for gaps in care at every office visit.
- Refer members to KHS' Health Education Diabetes Management Program by contacting the Health Education Department at 661-832-1590.
- Use appropriate billing codes, including CPT II quality tracking codes, which reduce the number of medical records your practice will need to provide KHS during MCAS audit season.
- Outreach to members with gaps in care or who miss appointments with letters, emails, reminder calls, and/or text messages.



Chlamydia Screening in Women (CHL)

Measure Description:

The percentage of women 16–24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year. Two methods identify sexually active women: pharmacy data (prescription contraceptives) and claim/encounter data (diagnoses or procedures indicating sexual activity, including pregnancy testing).

Required Exclusions:

Exclude members who meet either of the following criteria:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.

- Use appropriate billing codes.
- Check for gaps in care at every office visit.
- Perform annual chlamydia screening for all women 16 to 24 years of age who identify as being sexually active.
- Offer chlamydia screening urine test.
- Consider standing orders for STI screening.
- Place chlamydia swab in Pap test kits.
- Incorporate sexual history into the History and Physical.

Timeliness of Prenatal Care (PPC-Prenatal)

Measure Description:

The percentage of deliveries that received a prenatal care visit in the first trimester on or before the enrollment start date *or* within 42 days of enrollment in the organization.

The intent is to assess whether prenatal and preventive care was rendered on a routine, outpatient basis rather than assessing treatment for emergent events.

The prenatal care visit can be with *any* of the following:

• OB/GYN, or

PCP (must have a diagnosis of pregnancy to meet compliance), or

- Other prenatal care practitioners who deliver prenatal care services under the direction of an OB/GYN certified or accredited provider such as:
 - o Certified nurse midwife, or
 - o Nurse practitioner, or
 - o Physician assistant.

Required Exclusions:

Exclude members who meet *any* of the following criteria:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.

Medical Record Documentation:

*Services that occur over multiple visits count toward this measure if all services are within the time frame established in the measure. Ultrasound and lab results alone are not considered a visit; they must be combined with an office visit with an appropriate practitioner in order to count for this measure.

Documentation in the medical record must include a note indicating the date when the prenatal care visit occurred, and evidence as seen below:

- Documentation indicating the member is pregnant or references the pregnancy such as *one* of the following:
 - o Documentation in a standardized prenatal flow sheet.
 - o Documentation of last monthly period, EDD/EGA.
 - o A positive pregnancy test result.
 - o Documentation of gravidity and parity.
 - o Documentation of complete obstetrical history.
 - o Documentation of prenatal risk assessment and counseling/education.

- OR A basic physical obstetrical examination that includes *one* of the following:
 - Auscultation for fetal heart tone.
 - o Pelvic exam with obstetric observations.
 - o Measurement of fundus height (a standardized prenatal flow sheet may be used).
- OR Evidence that a prenatal care procedure was performed such as *one* of the following:
 - Screening test in the form of an obstetric panel (must include all of the following: hematocrit, differential WBC count, platelet count, hepatitis B surface antigen, rubella antibody, syphilis test, RBC antibody screen, Rh and ABO blood typing)
 - o TORCH antibody panel alone.
 - o Rubella antibody test/titer with an Rh incompatibility (ABO/Rh) blood typing.
 - o Ultrasound of a pregnant uterus.

- Use appropriate billing codes, including use of CPT II quality tracking codes to reduce the number of medical records your practice will need to provide KHS during MCAS audit season.
- Educate members on KHS' Baby Steps Program members can find details on the prenatal portion of the program in the Member Portal, or on our main website here: <u>Baby Steps program</u> | Kern Family Health Care.
- You can also find the Prenatal Reward Form here: <u>prenatal-reward-form 2023.pdf</u> (cloudinary.com)
- Have a direct referral process to OB/GYN in place.
- Educate staff to prioritize prenatal visits and schedule them within the first trimester.

Postpartum Care (PPC-Post)

Measure Description:

The percentage of deliveries that had a postpartum visit on or between 7 and 84 days after delivery. Do not include postpartum care provided in an acute inpatient setting.

The intent is to assess whether prenatal and preventive care was rendered on a routine, outpatient basis rather than assessing treatment for emergent events.

The postpartum visit can be with *any* of the following:

- OB/GYN, or
- PCP, or
- Other prenatal care practitioners who deliver prenatal care services under the direction of an OB/GYN certified or accredited provider such as:
 - o Certified nurse midwife, or
 - o Nurse practitioner, or
 - o Physician assistant.

Required Exclusions:

Exclude women who meet *any* of the following criteria:

- Delivery of non-live birth.
- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.

Medical Record Documentation:


*Services that occur over multiple visits count toward this measure if all services are within the time frame established in the measure and must be combined with an office visit with an appropriate practitioner in order to count for this measure.

Documentation in the medical record must include a note indicating the date when a postpartum visit occurred and *one* of the following:

- Pelvic exam or Pap test. A colposcopy alone is not compliant.
- Evaluation of weight, BP, breasts/notation of "breastfeeding", and abdomen.
- Notation of postpartum care, including but not limited to:
 - o Notation of "postpartum care", "PP care", "PP check", "6-week check".
 - o Preprinted "Postpartum Care" form in which information was documented during the visit.
- Perineal or cesarean incision/wound check.

- Screening for any *one* of the following:
 - o Depression,
 - o Anxiety,
 - o Tobacco use,
 - o Substance use disorder,
 - o Preexisting mental health disorders.
- Glucose screening for members with gestational diabetes.
- Documentation of any *one* of the following topics:
 - o Infant care or breastfeeding.
 - o Resumption of intercourse, birth spacing, or family planning.
 - o Sleep/fatigue.
 - o Resumption of physical activity.
 - o Attainment of healthy weight.

- Use appropriate billing codes, including use of CPT II quality tracking codes to reduce the number of medical records your practice will need to provide KHS during MCAS audit season.
- Educate members on KHS' Baby Steps Program members can find details on the postpartum portion of the program in the Member Portal, or on our main website here: <u>Baby Steps program | Kern Family Health Care</u>.
- Schedule cesarean section postop visits before members are discharged from hospital.
- For members undergoing a scheduled cesarean section, pre-schedule their post-op follow-up within the specified timeframe.
- Educate staff to prioritize postpartum visits and schedule them on or between 7 and 84 days after delivery.



Breast Cancer Screening (BCS-E)

Measure Description:

The percentage of members 50–74 years of age who were recommended for routine breast cancer screening *and* had a mammogram to screen for breast cancer.

Clinical Recommendation Statement:

The U.S. Preventive Services Task Force recommends screening women 50–74 years of age for breast cancer every 2 years. (B recommendation)

The Fenway Institute recommends that for patients assigned female at birth who have not undergone chest reconstruction (including those who have had breast reduction), breast/chest screening recommendations are the same as for cisgender women of a similar age and medical history.

The University of California San Francisco Center of Excellence for Transgender Health recommends that transgender men who have not undergone bilateral mastectomy, or who have only undergone breast reduction, undergo screening according to current guidelines for non-transgender women.

The World Professional Association for Transgender Health recommends health care professionals follow local breast cancer screening guidelines developed for cisgender women in their care of transgender and gender diverse people with breasts from natal puberty who have not had genderaffirming chest surgery.

Required Exclusions:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement period.
- Members who die any time during the measurement period.
- Members who had a bilateral mastectomy or both right and left unilateral mastectomies any time during the member's history through the end of the measurement period. Any of the following meet the criteria for bilateral mastectomy:
 - o Bilateral mastectomy
 - o Unilateral mastectomy with a bilateral modifier (CPT Modifier code 50) (same procedure).
 - Unilateral mastectomy found in clinical data with a bilateral qualifier value (SNOMED CT Modifier code 51440002) (same procedure).
- Any combination of codes from the lists below that indicate a mastectomy on both the left and right side on the same date of service or on different dates of service.
 - o Left Mastectomy:
 - Unilateral mastectomy with a left-side modifier (CPT Modifier code LT) (same procedure).
 - Unilateral mastectomy found in clinical data with a left-side qualifier value (SNOMED CT Modifier code 7771000) (same procedure).
 - Absence of the left breast.
 - Left unilateral mastectomy.

- o Right Mastectomy:
 - Unilateral mastectomy with a right-side modifier (CPT Modifier code RT) (same procedure).
 - Unilateral mastectomy found in clinical data with a right-side qualifier value (SNOMED CT Modifier code 24028007) (same procedure).
 - Absence of the right breast.
 - Right unilateral mastectomy.
- Members who had gender-affirming chest surgery (CPT code 19318) with a diagnosis of gender dysphoria any time during the member's history through the end of the measurement period.
- Members 66 years of age and older by the end of the measurement period, with frailty and advanced illness. Members must meet BOTH frailty and advanced illness criteria to be excluded.
- Members receiving palliative care any time during the measurement period.
- Members who had an encounter for palliative care (ICD-10-CM code Z51.5) any time during the measurement period.

- Use appropriate billing codes.
- Biopsies, breast ultrasounds, and MRIs do not count as appropriate primary breast cancer screening methods.
- Check for gaps in care at every office visit.
- Request results of mammograms ordered by other providers such as OB/GYNs and ensure the results are placed into the member's medical record.
- Outreach to members with gaps in care or who miss appointments with letters, emails, reminder calls, and/or text messages.

Cervical Cancer Screening (CCS)

Measure Description:

The percentage of members 21–64 years of age who were recommended for routine cervical cancer screening and were screened for cervical cancer using any of the following criteria:

- Members 21–64 years of age who had cervical cytology (PAP) performed within the last 3 years.
- Members 30–64 years of age who had cervical high-risk human papillomavirus (hrHPV) testing performed within the last 5 years.
- Members 30–64 years of age who had cervical cytology/high-risk human papillomavirus (hrHPV) cotesting within the last 5 years.

Required Exclusions:

Exclude women who meet *any* of the following criteria:

- Hysterectomy with no residual cervix any time during the member's history through December 31 of the measurement year.
- Cervical agenesis or acquired absence of cervix any time during the member's history through December 31 of the measurement year.
- Members who use hospice or palliative care services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.
- Members with Sex Assigned at Birth of Male at any time in the patient's history.

Medical Record Documentation:

Documentation in the medical record must include the following:

- A note indicating the date when the cervical cytology (PAP) or hrHPV test was performed.
- Generic documentation of "HPV test" can be counted as evidence of hrHPV test.
- The result or finding. "Unknown" is not considered a result/finding.
 - O Do not count biopsies, because they are diagnostic and therapeutic only and are not valid for primary cervical cancer screening.

- Check for gaps in care at every office visit.
- Request results of PAP tests performed by other providers such as OB/GYNs and ensure the results are placed into the member's medical record.

•	Outreach to members with gaps in care or who miss appointments with letters, emails, reminder calls, and/or text messages. Avoid missed opportunities by completing PAP tests during annual well-care visits.
	42